Jump to content


Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

  • Please log in to reply
No replies to this topic

#1 GerryL


    New Member

  • Members
  • Pip
  • 0 posts

Posted 10 February 2014 - 01:55 AM

This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 DASatinib versus Imatinib Study In treatment-Naive CML patients trial with a minimum follow-up of 3 years.


1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users